Xeris Biopharma (XERS) Expected to Announce Earnings on Wednesday

Xeris Biopharma (NASDAQ:XERS) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $58.54 million for the quarter.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $3.66 on Wednesday. The stock’s fifty day moving average is $3.50 and its two-hundred day moving average is $3.19. The firm has a market capitalization of $545.64 million, a P/E ratio of -8.13 and a beta of 2.61. Xeris Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $4.10.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on XERS. Jefferies Financial Group reissued a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research report on Monday, November 11th. Finally, HC Wainwright lifted their target price on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.